Table 4

Impact of vitamin E on ALT, AST, BMI and steatosis score in trials

Author and year	Outcomes with respect to control and intervention group
	ALT (U/L)			AST (U/L)			BMI (kg/m²)			Steatosis score
	Intervention	Control	P value	Intervention	Control	P value	Intervention	Control	P value	Intervention	Control	P value
Harrison et al , 200312	−12.3	−31	0.007	*	*	NR	−1.1	−1.6	0.012	NR	NR	NR
Vajro et al , 200418	−31.90† −24.09‡	−26.36† −29.9 2‡	0.54† 0.6 6‡	NR	NR	NR	NR	NR	NR	*	*	NR
Nobili et al , 200616	−36.35	−24.44	0.0001	−13.95	−10.05	0.001	−2.39	−1.83	0.0001	§	§	NR
Nobili et al , 200817	−31	−29	0.6	−12	−15	0.6	−3.7	−3.1	0.4	−1	0	0.07
Sanyal et al, 201015	−37	−20.1	0.001	−21.3	−3.8	<0.001	0.1	0.4	0.50	−1.026	−0.589	0.005
Lavine et al, 20116	−48.3	−35.2	0.07	−22.8	−20.4	0.32	−0.03	−0.01	0.78	−0.621	−0.399	0.18
Foster et al, 201113	*	NR	NR	*	NR	NR	NR	NR	NR	Decreased based on abdominal CT scan	NR	NR
Hoofnagle et al , 201314	−21.6	−5.1	NR	NR	NR	NR	NR	¶	NR	−0.7	−0.7	Vitamin E=<0.001 Placebo=<0.001
Aller et al , 20151	−3.7	−16.1	<0.05	−1	−5.6	<0.05	−5.1	−2.9	<0.05	*	*	NR

(−) Improvement in the outcome (mean response value − mean baseline value).
*Non-significant.
†Evaluation at month 2; this p value indicates difference between control and intervention group.
‡Evaluation at month 5; this p value indicates difference between control and intervention group.
§Steatosis was present in all biopsies, mostly macrovesicular, but frequently associated with microvesicular steatosis.
¶Significant improvement.
ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; NR, not reported.